Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016

•Ceftolozane/tazobactam (C/T) inhibits most Gram-negative pathogens from patients with lower respiratory infections in Asia-Pacific region.•C/T inhibits 81.9% of Klebsiella pneumoniae and 91.9% of Escherichia coli and is effective against ESBL-producing strains.•C/T effective against all P. aerugino...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of antimicrobial agents 2020-03, Vol.55 (3), p.105883-105883, Article 105883
Hauptverfasser: Kuo, Shu-Chen, Liu, Chun-Eng, Lu, Po-Liang, Chen, Yao-Shen, Lu, Min-Chi, Ko, Wen-Chien, Hsueh, Po-Ren, Chuang, Yin-Ching, Wang, Fu-Der
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Ceftolozane/tazobactam (C/T) inhibits most Gram-negative pathogens from patients with lower respiratory infections in Asia-Pacific region.•C/T inhibits 81.9% of Klebsiella pneumoniae and 91.9% of Escherichia coli and is effective against ESBL-producing strains.•C/T effective against all P. aeruginosa and carbapenem-non-susceptible strains (92.3% and 72.8% susceptibility, respectively). The aim of this study was to investigate the susceptibility of respiratory Gram-negative bacteria to ceftolozane/tazobactam and other antibiotics in the Asia-Pacific region during 2015-2016. MICs were determined using the CLSI standard broth microdilution method and interpreted accordingly. Pseudomonas aeruginosa (1574 isolates), Klebsiella pneumoniae (1226), Acinetobacter baumannii (627) and Escherichia coli (476) accounted for 73.1% of 5342 Gram-negative respiratory pathogens. Susceptibility to ceftolozane/tazobactam of individual Enterobacteriaceae was >80%, except for Enterobacter cloacae (76.6%). Ceftolozane/tazobactam inhibited 81.9% of K. pneumoniae and 91.9% of E. coli, with respective MIC50/MIC90 values of 0.5/>32 and 0.25/2 mg/L. For carbapenem-susceptible, ESBL-producing K. pneumoniae and E. coli, susceptibility was 65.5% and 93.3%, respectively, and respective MIC50/MIC90 values were 2/>32 and 0.5/2 mg/L. BlaCTX-M-1 group was most prevalent in selected ESBL-producing K. pneumoniae (40 of 54 isolates) and E. coli (15 of 22 isolates), with ceftolozane/tazobactam susceptibility rates of 50% and 80%, respectively. BlaSHV-ESBL was the second most prevalent, and ceftolozane/tazobactam inhibited 20% of 20 K. pneumoniae isolates with blaSHV-ESBL. The only effective antibiotics for carbapenem-non-susceptible K. pneumoniae (111 isolates) and E. coli (24 isolates) were amikacin and colistin. Ceftolozane/tazobactam was effective against almost all tested P. aeruginosa and carbapenem-non-susceptible strains, with susceptibility of 92.3% and 72.8%, respectively; the respective MIC50/MIC90 values were 1/4 and 2/>32 mg/L. The high susceptibility of ceftolozane/tazobactam remained in different age groups, patient locations, recovery times and countries, except Vietnam. In conclusion, ceftolozane/tazobactam was effective against most respiratory Gram-negative pathogens in the Asia-Pacific region; however, the emergence of carbapenem resistance mandates ongoing surveillance.
ISSN:0924-8579
1872-7913
DOI:10.1016/j.ijantimicag.2020.105883